214 results about "Macula Lutea" patented technology

The microstructure lens comprises a substrate, the substrate is provided with a bright vision area, a first optical area and a second optical area, and the first optical area and the second optical area are arranged around the bright vision area; the first optical area is located between the bright visual area and the second optical area and connected with the bright visual area and the second optical area. The bright vision area is used for generating a clear vision signal; the first microstructure array is arranged in the first optical area and is used for being matched with the substrate to provide a visual signal for stimulating the periphery of the retina; and the second microstructure array is arranged in the second optical area and is used for being matched with the substrate to provide at least two different visual signals for stimulating the periphery of the retina. The first optical area provides single-effect stimulation to compensate relative peripheral diopter close to the center of the retina macular, and lens wearing adaptability of a patient is considered; the second optical zone provides multiple-effect stimulation to compensate for gradually increasing relative peripheral diopter around the retina and delay the time of drug resistance generation of the product, thereby enhancing myopia management efficacy and prolonging efficacy time.

The invention provides a two-stage current intensity adjusting method for an eye therapeutic apparatus, and the method comprises the steps: extracting the impedance effect intensity of a current at a macular center through recognizing the thickness of an impedance barrier layer corresponding to the current limiting degree of a high-impedance region, and combining with the actual penetration thickness, and obtaining the current penetration depth reduction proportion of the current penetration depth at the macular center; the current intensity imbalance degree of the coarse adjustment basic current intensity in the transition subarea is evaluated, and by obtaining the current intensity increase and decrease multiple of the fine adjustment compensation current intensity, the gradient difference between high impedance limitation and low impedance permeation is integrated, and the current intensity is compensated to balance the current intensity imbalance degree of the transition subarea; and updating the current output power level of each partition according to the fine adjustment compensation current intensity, and feeding back the current output power level to a therapeutic instrument circuit in real time to obtain uniform therapeutic intensity distribution so as to be matched with the decreasing proportion of impedance of impedance gradient distribution from high to low.

Diabetes is a disease characterized by high levels of blood glucose. It is important to keep diabetes under control to avoid short- and long-term complications. Diabetes can affect vision due to the alterations it produces in the blood vessels of the retina. This is known as Diabetic Retinopathy (DR), which is one of the leading causes of impaired vision in developed countries. One of the complications of diabetic retinopathy is Diabetic Macular Edema (DME), which is the leading cause of vision loss in diabetic patients and can appear at any stage of diabetic retinopathy. This consists of the gradual accumulation of fluid in the macula, the most important area of the retina. The determination of diabetic macular oedema is very important for the retina. The determination of diabetic macular oedema is very important for adequate treatment of this condition. A variety of technological options are used for detecting diabetic retinopathy, although only the most sophisticated detect macular oedema, a complication that appears as a consequence of diabetic retinopathy and is one of the leading causes of blindness. The invention describes a portable system for detecting diabetic macular oedema by capturing a fundus image using a portable ophthalmoscope; said image is sent via wired or wireless means to an embedded system that has an algorithm based on artificial intelligence, which extracts information from the image and processes same to identify the presence of the condition being studied.

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The invention relates to a diabetic retinopathy fundus photography grading report system combined with a clinical guide, based on an artificial intelligence deep learning technology, and belongs to the field of fundus lesion analysis. The system accurately identifies and segments various lesions such as microhemangioma, bleeding, exudation and the like and symbolic structures such as optic discs, macular regions and the like by automatically analyzing fundus photographic images. The system adopts ICDR international standards to grade diabetic retinopathy, and provides diagnosis and treatment suggestions for lesion characteristics in combination with clinical guidelines of American ophthalmology institute in 2019. Through big data training, the system can generate detailed reports in real time, the early screening rate is remarkably improved, misdiagnosis and missed diagnosis are reduced, and the diagnosis speed and accuracy are improved. The system comprises a plurality of modules, such as an image pre-classification module, a deep learning focus recognition module, an ICDR grading module and a report generation module, efficient and accurate diabetic retinopathy diagnosis and grading are cooperatively achieved, and the clinical management level is improved.

Described is an ophthalmic device that contains visible light filters. The ophthalmic device is a free radical reaction product of a reactive mixture comprising: one or more monomers suitable for making the ophthalmic device; a first visible light filtering compound, the first visible light filtering compound having a visible light absorption maximum between 430 and 480 nm and a full width half maximum (FWHM) at the visible light absorption maximum of at least 35 nm and up to 150 nanometers, wherein the compound is photostable, and wherein the compound has a molar extinction coefficient of at least 7740 L·mol−1·cm−1; and a second visible light filtering compound. The devices may provide one or more benefits to wearers, including enhanced macular pigment optical density (MPOD), as well as improved color perception and color enhancement.

Illustrative methods and devices for providing stimulus to the eye to treat vision disorders. Systems and methods for testing thresholds and configuring the stimulation for a patient are provided. Various examples may include therapies for vision disorders that can progress to blindness, such as macular degeneration or other diseases and disease processes.

This invention discloses an ophthalmic disease diagnostic system based on optical coherence tomography (OCT), comprising: an image data acquisition module for acquiring OCT image data; a feature extraction and similarity calculation module for extracting OCT image feature representations and layered structural features of the macular region, calculating macular structural similarity information between different OCT image data, and constructing a structural similarity alignment matrix reflecting the structural similarity among all OCT images; simultaneously constructing an association matrix representing the correspondence between OCT images and disease categories; and a model training module that introduces the structural similarity alignment matrix and association matrix as joint supervision signals into the objective function, adaptively learning to obtain an ophthalmic disease diagnostic model; the ophthalmic disease diagnostic model outputs a classification diagnostic result representing the probability that the input OCT image data belongs to various ophthalmic diseases. This invention achieves automatic identification and classification of ophthalmic diseases, with high diagnostic accuracy and good robustness.

Based on co-drugs representing two different chemical entities and the co- and sequential administration of the two chemical entities, novel therapies for macular degeneration and TTR amyloidosis are provided. The first component (“selective TTR ligand”) is a chemical entity that binds to TTR in the RBP4 (retinol-binding protein 4)-TTR (transthyretin) complex, which participates in the delivery of retinol to the retina. This component reduces retinol transport from circulation to the retina and provides stabilization of the TTR tetramer. The second component (“C20-D3-visual chromophore-generating compound”) is a C20-D3 modified retinoid or carotenoid that, when metabolized in mammals, ultimately produces a C20-D3 visual chromophore, which is presented in the retina as C20-D3-9-cis-retinal or C20-D3-11-cis-retinal. Deuteration at C20 reduces the formation of lipofuscin biretinol, but other functions (such as providing a precursor for the synthesis of the visual chromophore 11-cis-retinaldehyde in vivo) are not reduced.

The invention provides a nanoparticle penetrating cornea as well as a preparation method and application thereof. The nanoparticle comprises a cationic liposome G2-C14, an inner core formed by aliphatic polyester and an amphiphilic polymer, and a shell modified by polysaccharide, the hydrophobic drug and the siRNA are loaded in the inner core. According to the nano-particles provided by the invention, through polysaccharide surface modification, ocular surface adhesion and trans-epithelium transport capability are enhanced, multi-barrier penetration of the eye is realized, the nano-particles are effectively delivered to a focus area of posterior segment of the eye, the delivered siRNA targets to silence the expression of age-related macular degeneration pathogenic genes, and the hydrophobic drug removes active oxygen and inhibits release of inflammatory factors, so that the anti-aging effect of the nano-particles is improved. The focus thickness is synergistically reduced.

The application discloses a macular hole postoperative recovery effect classification method based on OCT images, and comprises the following steps: constructing an OCT image dataset, training and verifying a model; introducing an adaptive model authority coefficient for the differences in the judgment of different deep learning models, and performing model integrated decision support to classify the rehabilitation effect; performing model hyperparameter optimization and deep learning model training and verification; and using the trained deep learning model to classify the macular hole disease rehabilitation effect. The macular hole disease rehabilitation effect classification intelligent implementation method based on OCT images provides a computer-aided tool for clinicians, and can provide quantitative analysis result support for preoperative discussion.

The application discloses an AMD efficacy prediction method, system, device and medium based on feature fusion, belongs to the technical field of efficacy prediction, and comprises the following steps: acquiring optical coherence tomography image data and demographic characteristics of an age-related macular degeneration patient; determining deep learning features and imaging features according to the optical coherence tomography image data; performing feature selection based on the deep learning features, the imaging features and the demographic characteristics to obtain input features; performing calculation by combining a time series analysis network with the input features to determine a hidden state; and performing feature change trend analysis according to the hidden state to determine an age-related macular degeneration efficacy prediction result. The application proposes a multi-feature fusion long short-term memory network, and realizes efficacy prediction of anti-vascular endothelial growth factor treatment for the age-related macular degeneration patient.

The invention discloses application of cnidium lactone in preparation of a medicine for treating AMD or corneal injury, and belongs to the field of biological medicine. It is found for the first time that the cnidium lactone can inhibit sodium iodate induced retinal pigment epithelial cell injury, and it is also found for the first time that the cnidium lactone can promote injured cornea repair; based on the discovery, the invention respectively provides application of cnidium lactone in preparation of medicines for treating age-related macular degeneration and preparation of medicines for treating corneal injury. Experimental results show that cnidium lactone can remarkably reverse the retinal pigment epithelial cell degradation trend caused by age-related macular degeneration and can also remarkably promote corneal notch healing. The invention provides a new optional medicine for treating age-related macular degeneration and corneal injury, expands the application range of cnidium lactone, and has outstanding clinical practical value and wide application prospect.

To provide a deep neural network framework for processing OCT images to predict treatment intensity.SOLUTION: Systems and methods relate to processing optical tomography coherence (OCT) images to predict characteristics of treatment to be administered to effectively treat age-related macular degeneration. The processing may include pre-processing the image by flattening and / or cropping the image (230), and processing the pre-processed image using a neural network (235). The neural network may include a deep convolutional neural network. An output of the neural network can indicate a predicted frequency and / or interval at which treatment (e.g., anti-vascular endothelial growth factor therapy) is to be administered so as to prevent leakage of vasculature in the eye (240).SELECTED DRAWING: Figure 2

The application relates to the technical field of ophthalmic surgical instruments, in particular to an ophthalmic internal limiting membrane tampon, which can protectively and automatically rebound when the tampon is operated with excessive force during a'mechanical' tampon process, so as to prevent iatrogenic retinal pigment epithelial layer damage at the bottom of a macular hole. The device comprises a sleeve-shaped handle, a spring and a probe are arranged in the handle along the length direction of the handle; the probe comprises a probe main body and a probe base, and the two ends of the probe base are connected with the spring and the probe main body respectively; an outer thread is arranged on the outer side of the probe base, and a tensioning wheel is arranged on the handle; the outer thread is divided into at least three thread regions arranged along the length direction of the probe base, including a first thread region, a second thread region and a third thread region; the threads in the first thread region, the second thread region and the third thread region correspond to first threads, second threads and third threads respectively; and the diameters of the second threads are all larger than the diameters of the first threads and the third threads.

The invention relates to the technical field of image processing, in particular to a macular region retina layered structure automatic segmentation system based on an OCT image. The system comprises a memory and a processor, and the processor executes computer programs stored in the memory to implement the following steps: acquiring an OCT image of a retina, and determining an ILM boundary and a complex region based on the gray level of pixel points; obtaining a BM boundary according to the gray scale change characteristics of each column of pixel points in the complex body region; determining a shielding area and a target normal area based on the position of the BM boundary, and further determining an RPE boundary; dividing an abnormal region according to the gray scale relative size of region pixel points between the RPE boundary and the BM boundary in the target normal region, and determining a raised boundary and a normal boundary; and repairing the lifted boundary, and obtaining a macular region retina layered structure segmentation result in combination with a repairing result and a normal boundary. According to the invention, the accuracy of the segmentation result of the macular region retina layered structure is improved.

The application is a kind of home amblyopia afterimage therapeutic instrument, belonging to the field of eye optometry amblyopia treatment. The application provides an economic home amblyopia afterimage therapeutic instrument and its operation method with good stability, high accuracy of macular fovea covering protection, low requirement of cooperation of the operator and the patient and applicability to wide-angle para-central fixation amblyopia patients by the integration design of multiple systems, especially the use of three-dimensional translation table to adjust the light source position and present the fundus image on the display screen, and the operation guidance by the voice prompting system, and the use of topological light source for saturated illumination. The application is mainly applied to the home treatment of para-central fixation amblyopia patients, and can also be applied to the hospital treatment, reducing the work burden of doctors and nurses.

Illustrative methods and devices for providing stimulus to the eye to treat vision disorders. Systems and methods for feedback relating to the stimulus itself as well as the effect of such stimulus on the patient are provided. Various examples may include therapies for vision disorders that can progress to blindness, such as macular degeneration or other diseases and disease processes.

A low-cost line-field parallel swept-source optical coherence tomography (OCT) system suitable for home monitoring of diabetic retinopathy and other disease states including macular degeneration is disclosed. The system includes a tunable laser coupled to an interferometer and a line-scan detector, and a single-board computer configured to control laser tuning and acquire interference data. A fixation target display is positioned to project an image to a patient's eye, and is moved in discrete steps orthogonal to the projected OCT scanline to acquire multiple B-scans at different retinal positions without mechanical beam scanning. The fixation target movement enables cross-sectional or volumetric retinal imaging using a single fixed OCT scanline, reducing system complexity and cost. The single-board computer processes line-field interferograms into depth-resolved profiles, displays images, and controls fixation target positioning. The system enables early detection and monitoring of diabetic macular edema and other retinal complications in a compact, patient-operable configuration.

The present disclosure provides an augmented reality (AR) device for patients with retinitis pigmentosa and macular degeneration comprising a map providing unit, a region setting unit, and a region display unit, wherein the map providing unit sequentially drives a plurality of scanning points included in a display of wearable glasses to provide a scotoma map wherein a user's scotoma is checked according to the user's input signal, the region setting unit sets the user's scotoma region based on the scotoma map; the region display unit displays an external image corresponding to the scotoma region in a display region included in the display.

A patient's visual health can be evaluated via a virtual reality (VR) system, which can include a VR headset in electronic communication with a computing device. The computing device can cause a phenomenon (such as a visual test or an image) to be displayed on the screens of the VR headset. Using varying combinations of sensors, cameras, probes, and microphones, the VR headset collects data about the patient as she perceives and responds to the phenomenon. Optionally, the computing device can alter the phenomenon and analyze the patient's perception and responses to evaluate the patient for macular degeneration. Optionally, the computing device can alter the phenomenon based on the patient's perception and responses.

The present disclosure describes compositions comprising vitamin C, vitamin E, zinc, copper, lutein, zeaxanthin, and Coenzyme Q10, as well as pharmaceutically acceptable salts of any one of the foregoing. The compositions are useful for treating diseases associated with loss of visual acuity, including, for example, age-related macular degeneration, and supporting cardiac health.

To enable understanding of choroidal asymmetry. [Solution] In choroidal vascular images, the direction of blood vessel course is determined for each of several pairs of analysis points that are symmetrical with respect to the line connecting the macula and the optic nerve head. The asymmetry of each pair of analysis points is analyzed from the direction of blood vessel course of each analysis point, and the pair of analysis points with asymmetry is highlighted by enclosing them in a frame.

Carotenoid compositions are described for management, treatment, and / or prevention of stress by reducing cortisol levels and / or improving distribution and / or density of macular pigment and thus improving overall health status. More particularly, a subject in need thereof for the method has disturbed macular pigment optical density or increased levels of cortisol as markers of psychological and physiological stress. Methods are also described of administering macular carotenoid compositions in daily doses of at least or about 0.005 mg / kg body weight of lutein, and at least or about 0.001 mg / kg body weight of meso-zeaxanthin and zeaxanthin isomer along with at least one food grade excipient and evaluating overall health status. The composition may be derived from plant extract containing xanthophylls and / or xanthophylls esters. The composition also reduces cortisol levels in the blood and relieves physiological stress, thus improving overall health status of a subject in need thereof.

The invention belongs to the technical field of medical experimental animal models, provides a construction method of a dry age-related macular degeneration animal model, and aims to break through the technical bottlenecks of long construction period, high cost and incomplete pathological feature coverage of an existing model. D-galactose is used for inducing glycosylation end product accumulation and mitochondrial dysfunction, oxidative stress, RPE metabolic disorder and inflammation microenvironment in the dry AMD pathogenesis process can be synchronously simulated, core pathological characteristics such as retina glass membrane wart deposition, RPE atrophy, retina and visual function damage and the like can be accurately reproduced, meanwhile, a multi-dimensional verification system is matched, and the method has the advantages that the method is simple and convenient to operate and high in practicability. The method is suitable for preclinical evaluation of personalized treatment strategies; besides, the method is short in modeling period, the animal model meeting the requirement can be obtained within 8 weeks, the cost advantage is outstanding, and an efficient and reliable experimental animal model can be provided for dry AMD treatment research.

The invention discloses a myopic maculopathy fundus color photo image classification method and system, and belongs to the technical field of image classification. Obtaining a to-be-analyzed fundus color photo; preprocessing the fundus color photo to extract an effective view area and reduce image acquisition difference interference; and inputting the preprocessed image into a deep learning classification network, and outputting an META-PM classification result corresponding to the myopic maculopathy. According to the method, on the premise of not depending on accurate focus labeling, the global structure and the local focus evidence are fused at the same time, the ordered level relation is explicitly modeled, and the cross-device robustness and the long-tail distribution adaptability are improved.

The application relates to an identification method and device, computer equipment and a storage medium. The method comprises the following steps: obtaining a blood vessel image of an eye to be examined, the blood vessel image being generated by optical coherence tomography blood vessel imaging; obtaining statistical features of a macular region in the blood vessel image; and identifying a non-perfusion region in the blood vessel image based on the statistical features. The method can effectively improve the flexibility of identifying the non-perfusion region.

The invention relates to a corneo-capsular protection system (CCPS), which is an ophthalmological device designed to simultaneously protect the corneal endothelium and the posterior capsule during intraocular surgery (phacoemulsification), the system comprising a corneal protection dome (CPD) and a capsular protection floor (CPF). The dome is a foldable, transparent lens that protects the endothelium against mechanical and thermal damage while optionally providing a magnifying effect to improve surgical visibility. The floor is a foldable lens designed to protect the posterior capsule from perforations and trauma. It has a central condensation facilitating its safe removal, and can also provide protection to the macula against prolonged exposure to light. The two components are designed for easy insertion and removal through micro-incisions, thereby reducing the risk of postoperative complications, and have a complete, potentiated protective effect if used in combination.